Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W J Storkus

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
The Journal of Clinical Investigation|October 1, 1996
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigenM J Maeurer, S M Gollin, D Martin, et al.
Cancer Research|January 1, 1994
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivoH Tahara, H J Zeh, W J Storkus, et al.
Gene Therapy|February 12, 1998
Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor modelsT Tüting, A Gambotto, J Baar, et al.
The Journal of Experimental Medicine|January 1, 1995
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytesC Castelli, W J Storkus, M J Maeurer, et al.
Gene Therapy|March 9, 2007
Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunityT Tatsumi, T Takehara, S Yamaguchi, et al.
British Journal of Cancer|December 18, 2001
gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cellsL S Kierstead, E Ranieri, W Olson, et al.
The Journal of Experimental Medicine|April 1, 1996
Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccinesJ I Mayordomo, D J Loftus, H Sakamoto, et al.
Molecular Immunology|December 2, 2008
Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccineM Gigante, A Blasi, A Loverre, et al.
Cellular Immunology|August 1, 1997
FLT3 ligand induces the generation of functionally active dendritic cells in miceM R Shurin, P P Pandharipande, T D Zorina, et al.
Nature Medicine|December 1, 1995
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunityJ I Mayordomo, T Zorina, W J Storkus, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
The Journal of Clinical Investigation|October 1, 1996
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigenM J Maeurer, S M Gollin, D Martin, et al.
Cancer Research|January 1, 1994
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivoH Tahara, H J Zeh, W J Storkus, et al.
Gene Therapy|February 12, 1998
Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor modelsT Tüting, A Gambotto, J Baar, et al.
The Journal of Experimental Medicine|January 1, 1995
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytesC Castelli, W J Storkus, M J Maeurer, et al.
Gene Therapy|March 9, 2007
Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunityT Tatsumi, T Takehara, S Yamaguchi, et al.
British Journal of Cancer|December 18, 2001
gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cellsL S Kierstead, E Ranieri, W Olson, et al.
The Journal of Experimental Medicine|April 1, 1996
Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccinesJ I Mayordomo, D J Loftus, H Sakamoto, et al.
Molecular Immunology|December 2, 2008
Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccineM Gigante, A Blasi, A Loverre, et al.
Cellular Immunology|August 1, 1997
FLT3 ligand induces the generation of functionally active dendritic cells in miceM R Shurin, P P Pandharipande, T D Zorina, et al.
Nature Medicine|December 1, 1995
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunityJ I Mayordomo, T Zorina, W J Storkus, et al.
Pageof 8